Conflict of Interest
The European VALHUDES is a researcher-induced study, coordinated by University of Milano-Bicocca (Monza, Italy), Sciensano (Bruxelles, Belgium), Istituto Europeo di Oncologia (Milan, Italy), University of Sassari (Sassari, Italy), U.O. Coordinamento Consultori Familiari, ASSL Sassari – ATS Sardegna (Sassari, Italy), NHS Lothian, University of Edinburgh (Edinburgh, Scotland), Trinity College Dublin (Dublin, Ireland).
Manufacturers of HPV assays (GeneFirst, Oxford, UK and Hiantis, Milan, Italy) and devices (Copan Italia Spa, Brescia, Italy and Novosanis, Belgium) participated in the European VALHUDES framework contributing equipment for laboratory testing under the condition of accepting independent publication of results. The study group received free self-sample collection devices from Copan Italia Spa (Brescia, Italy) and Novosanis (Belgium) and free OncoPredict HPV assay from (Hiantis, Milan, Italy). CEC declares to have received research support from BD Diagnostics, Seegene, Arrows Diagnostics, Copan, GeneFirst, Hiantis and VITRO. CEC is a minority shareholder of Hiantis. ADI, AFP, FB, FO, GT, HE, KC, MM, CG, RP declare no conflict of interest.